Abstract:Despite the massive investment in Alzheimer's disease (AD), there are still no disease-modifying treatments (DMTs) for AD. One major reason is attributed to the limitation of clinical "one-size-fits-all" approach, since the same AD treatment solely based on clinical diagnosis was unlikely to achieve good clinical efficacy. In recent years, computational approaches based on multiomics data have provided an unprecedented opportunity for drug discovery since they can substantially lower the costs and boost the efficiency. In this study, we intended to identify potential drug candidates for different pathological stages of AD by computationally repurposing Food and Drug Administration (FDA) approved drugs. First, we assembled gene expression data from three different AD pathological stages, which include mild cognitive impairment (MCI) and early and late stages of AD (EAD, LAD). We next quantified the network distances between drug target networks and AD modules by utilizing a network proximity approach, and identified 193 candidates that possessed significant associations with AD. After searching for previous literature evidence, 63 out of 193 (32.6%) predicted drugs were demonstrated to exert therapeutic effects on AD. We further explored the novel mechanism of action (MOA) for these drug candidates by determining the specific brain cells they might function on based on AD patient single cell transcriptomic data. Additionally, we selected several promising candidates that could cross the blood brain barrier together with confirmed neuroprotective effects, and subsequently determined the antioxidative activity of these compounds. Experimental results showed that azathioprine decreased the reactive oxygen species (ROS) and malondialdehyde (MDA) levels and improved the superoxide dismutase (SOD) activity in APP-SH-SY5Y cells. Finally, we deciphered the potential MOA of azathioprine against AD via network analysis and validated several apoptosis-related proteins (Caspase 3, Cleaved Caspase 3, Bax, Bcl2) through western blotting. In summary, this study presented an effective computational strategy utilizing omics data for AD drug repurposing, which provides a new perspective for drug discovery and development.

STOP‐AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer's disease

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease

Screening Novel Drug Candidates for Alzheimer's Disease by an Integrated Network and Transcriptome Analysis.

Drug Repurposing for Effective Alzheimer's Disease Medicines: Existing Methods and Novel Pharmacoepidemiological Approaches

Virtual screening of lead compounds for the treatment of Alzheimer's disease based on multi-target strategy

Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.

Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach

High-Throughput Screening and Molecular Dynamics Simulation of Natural Product-like Compounds against Alzheimer’s Disease through Multitarget Approach

Modeling Path Importance for Effective Alzheimer's Disease Drug Repurposing

Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease

Repurposed agents in the Alzheimer’s disease drug development pipeline

Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐AD

Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

Hybrid neural network approaches to predict drug-target binding affinity for drug repurposing: screening for potential leads for Alzheimer's disease

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease

DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer's Disease

Neuropathological stage‐dependent proteome mapping of the olfactory tract in Alzheimer's disease: From early olfactory‐related omics signatures to computational repurposing of drug candidates

Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease

A Novel Method for Drug Screen to Regulate G Protein-Coupled Receptors in the Metabolic Network of Alzheimer's Disease.